行情

PFNX

PFNX

PFENEX
AMEX

实时行情|Nasdaq Last Sale

8.52
+0.46
+5.71%
交易中 15:39 04/02 EDT
开盘
7.77
昨收
8.06
最高
8.66
最低
7.77
成交量
17.37万
成交额
--
52周最高
14.00
52周最低
5.25
市值
2.91亿
市盈率(TTM)
3872.73
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PFNX价格均价为18.67,最高价位20.00,最低价为17.00。

EPS

PFNX 新闻

更多
  • Edited Transcript of PFNX earnings conference call or presentation 11-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 2天前
  • Should You Worry About Pfenex Inc.'s (NYSEMKT:PFNX) CEO Pay Cheque?
  • Simply Wall St. · 03/16 12:47
  • Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 01:46
  • Pfenex EPS beats by $0.13, beats on revenue
  • seekingalpha · 03/12 01:10

所属板块

生物技术和医学研究
+1.67%
制药与医学研究
+1.64%

热门股票

代码
价格
涨跌幅

PFNX 简况

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
展开

微牛提供Pfenex Inc(AMEX-PFNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PFNX股票新闻,以帮助您做出投资决策。